Skip to main content
AAN.com

Abstract

Objective

To test the hypothesis that the inflammatory marker plasma soluble CD14 (sCD14) associates with incident dementia and related endophenotypes in 2 community-based cohorts.

Methods

Our samples included the prospective community-based Framingham Heart Study (FHS) and Cardiovascular Health Study (CHS) cohorts. Plasma sCD14 was measured at baseline and related to the incidence of dementia, domains of cognitive function, and MRI-defined brain volumes. Follow-up for dementia occurred over a mean of 10 years (SD 4) in the FHS and a mean of 6 years (SD 3) in the CHS.

Results

We studied 1,588 participants from the FHS (mean age 69 ± 6 years, 47% male, 131 incident events) and 3,129 participants from the CHS (mean age 72 ± 5 years, 41% male, 724 incident events) for the risk of incident dementia. Meta-analysis across the 2 cohorts showed that each SD unit increase in sCD14 was associated with a 12% increase in the risk of incident dementia (95% confidence interval 1.03–1.23; p = 0.01) following adjustments for age, sex, APOE ε4 status, and vascular risk factors. Higher levels of sCD14 were associated with various cognitive and MRI markers of accelerated brain aging in both cohorts and with a greater progression of brain atrophy and a decline in executive function in the FHS.

Conclusion

sCD14 is an inflammatory marker related to brain atrophy, cognitive decline, and incident dementia.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Henriksen K, O'Bryant SE, Hampel H, et al. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 2014;10:115–131.
2.
Ryan LA, Zheng J, Brester M, et al. Plasma levels of soluble CD14 and tumor necrosis factor-α type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis 2001;184:699–706.
3.
Sahay B, Patsey RL, Eggers CH, Salazar JC, Radolf JD, Sellati TJ. CD14 signaling restrains chronic inflammation through induction of p38-MAPK/SOCS-dependent tolerance. PLoS Pathog 2009;5:e1000687.
4.
Reed-Geaghan EG, Reed QW, Cramer PE, Landreth GE. Deletion of CD14 attenuates AD pathology by influencing the brain's inflammatory milieu. J Neurosci 2010;30:15369–15373.
5.
Liu Y, Walter S, Stagi M, et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 2005;128:1778–1789.
6.
Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study: design and preliminary data. Prev Med 1975;4:518–525.
7.
Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993;3:358–366.
8.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Text Revision. Arlington: American Psychiatric Association; 2000.
9.
McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–944.
10.
Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–260.
11.
Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 2016;374:523–532.
12.
Folstein MF, Folstein SE, McHugh PR. “Mini mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
13.
Bachman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992;42:115–119.
14.
Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker JT, Beauchamp N. Evaluation of dementia in the Cardiovascular Health Cognition Study. Neuroepidemiology 2003;22:1–12.
15.
Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc 2004;52:195–204.
16.
Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822–838.
17.
DeCarli C, Massaro J, Harvey D, et al. Measures of brain morphology and infarction in the Framingham Heart Study: establishing what is normal. Neurobiol Aging 2005;26:491–510.
18.
Kuller LH, Arnold AM, Longstreth WT Jr, et al. White matter grade and ventricular volume on brain MRI as markers of longevity in the Cardiovascular Health Study. Neurobiol Aging 2007;28:1307–1315.
19.
Yue NC, Arnold AM, Longstreth WT Jr, et al. Sulcal, ventricular, and white matter changes at MR imaging in the aging brain: data from the Cardiovascular Health Study. Radiology 1997;202:33–39.
20.
Kuller LH, Longstreth WT Jr, Arnold AM, Bernick C, Bryan RN, Beauchamp NJ Jr. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. Stroke 2004;35:1821–1825.
21.
Tao Q, Ang TFA, DeCarli C, et al. Association of chronic low-grade inflammation with risk of Alzheimer disease in ApoE4 carriers. JAMA Netw Open 2018;1:e183597.
22.
Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007;28:521–574.
23.
Uchoa MF, Moser VA, Pike CJ. Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors. Front Neuroendocrinol 2016;43:60–82.
24.
Buckley RF, Mormino EC, Rabin JS, et al. Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults: association of global amyloid and regional tau deposition measured by positron emission tomography. JAMA Neurol 2019;76:542–551.
25.
Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci 2009;29:11982–11992.
26.
Fassbender K, Walter S, Kuhl S, et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J 2004;18:203–205.
27.
Bate C, Veerhuis R, Eikelenboom P, Williams A. Microglia kill amyloid-beta1-42 damaged neurons by a CD14-dependent process. Neuroreport 2004;15:1427–1430.
28.
Beschorner R, Nguyen TD, Gozalan F, et al. CD14 expression by activated parenchymal microglia/macrophages and infiltrating monocytes following human traumatic brain injury. Acta Neuropathol 2002;103:541–549.
29.
Longenecker CT, Jiang Y, Orringer CE, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014;28:969–977.
30.
Lee JW, Cho E, Kim MG, Jo SK, Cho WY, Kim HK. Proinflammatory CD14+CD16+ monocytes are associated with vascular stiffness in predialysis patients with chronic kidney disease. Kidney Res Clin Pract 2013;32:147–152.
31.
Vrijenhoek JE, Pasterkamp G, Moll FL, et al. Extracellular vesicle-derived CD14 is independently associated with the extent of cardiovascular disease burden in patients with manifest vascular disease. Eur J Prev Cardiol 2015;22:451–457.
32.
Trøseid M, Nestvold TK, Nielsen EW, Thoresen H, Seljeflot I, Lappegård KT. Soluble CD14 is associated with markers of vascular dysfunction in bariatric surgery patients. Metab Syndr Relat Disord 2015;13:119–124.
33.
Beschorner R, Schluesener HJ, Gözalan F, Meyermann R, Schwab JM. Infiltrating CD14+ monocytes and expression of CD14 by activated parenchymal microglia/macrophages contribute to the pool of CD14+ cells in ischemic brain lesions. J Neuroimmunology 2002;126:107–115.
34.
Granucci F, Zanoni I. Role of CD14 in host protection against infections and in metabolism regulation. Front Cell Infect Microbiol 2013;3:32.
35.
Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 2002;23:301–304.
36.
Kamer AR, Dasanayake AP, Craig RG, Glodzik-Sobanska L, Bry M, de Leon MJ. Alzheimer's disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis. J Alzheimer's Dis 2008;13:437–449.
37.
Reiner AP, Lange EM, Jenny NS, et al. Soluble CD14: genome-wide association analysis and relationship to cardiovascular risk and mortality in the older adults. Arterioscler Thromb Vasc Biol 2013;33;158–164.
38.
Ho JE, Lyass A, Courchesne P, et al. Protein biomarkers of cardiovascular disease and mortality in the community. J Am Heart Assoc 2018;7:e008108.
39.
Pase MP, Beiser AS, Himali JJ, et al. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol 2019;76:598–606.
40.
Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-beta biomarkers for Alzheimer's disease. Nature 2018;554:249–254.
41.
Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease: longitudinal plasma neurofilament light and neurodegeneration in Alzheimer disease. JAMA Neurol 2019;76:791–799.

Information & Authors

Information

Published In

Neurology®
Volume 94Number 3January 21, 2020
Pages: e254-e266
PubMed: 31818907

Publication History

Received: January 22, 2019
Accepted: July 18, 2019
Published online: December 9, 2019
Published in print: January 21, 2020

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

M.P.P. is funded by a National Heart Foundation of Australia Future Leader Fellowship (102,052). The Framingham Heart Study is supported by the National Heart, Lung, and Blood Institute (contract no. N01-HC-25195 and no. HHSN268201500001I) and by grants from the National Institute on Aging (R01 AG054076, R01 AG049607, R01 AG058589, R01 AG059421, U01 AG049505, U01 AG052409) and the National Institute of Neurologic Disorders and Stroke (NS017950 and UH2 NS100605 as part of MarkVCID). H.J.A. is supported by a National Institute on Aging Research Supplement to Promote Diversity in Health-Related Research (R01AG054076-02S1) and through support from Boston University School of Medicine's Jack Spivack Neuroscience scholarship and Aram V. Chobanian Assistant Professorship. C.D. directs the UC Davis Alzheimer's Disease Center with funding from the NIH (P30 AG010182). CHS research was supported by contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and N01HC15103, and grants U01HL080295 and U01HL130114 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurologic Disorders and Stroke. Additional support was provided by R01AG023629, R01AG15928, and R01AG20098 from the National Institute on Aging. A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org.

Authors

Affiliations & Disclosures

Matthew P. Pase, PhD*
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Alzheimer's Disease
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship. APP1089698. PI. 2015-2018, (2) Australian National Health and Medical Research Council (NHMRC) Project Grant. APP1158384. PI. 2019- 2023.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) National Heart Foundation of Australia, (2) Alzheimer's Association, (3) National Stroke Foundation, (4) Bethlehem Griffiths Research Foundation.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jayandra J. Himali, PhD*
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Alexa S. Beiser, PhD
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
Brooks Cole, Introductory Applied Statistics, 2005
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NINDS, biostatistician, 2 R01 NS017950-28, 2009-2014 NIH/NIA, biostatistician, 5 R01 AG08122, 2005-2010 NIH/NIA, biostatistician, 2 R01 AG16495, 2005-2010 NIA/NINDS, biostatistician, 1 R01 AG033040-01, 2009-2013 NIH/NHLBI, biostatistician, R01 HL093029-01A1, 2009-2011
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Charles DeCarli, MD
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
1) Novartis Pharmaceuticals
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1)Novartis Pharmaceuticals
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
National Institutes of Health
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Emer R. McGrath, MD, PhD https://orcid.org/0000-0002-3589-2964
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Alzheimer’s Association
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Claudia L. Satizabal, PhD https://orcid.org/0000-0002-1115-4430
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Hugo J. Aparicio, MD, MPH
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Dr. Aparicio is funded by NIH grants R01-AG054076-02S1 and L30 NS093634.
Research Support, Academic Entities:
1.
(1) Boston University’s Aram V. Chobanian Assistant Professorship
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Hieab H.H. Adams, MD, PhD
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Alexander P. Reiner, MD, MSc
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
W.T. Longstreth Jr, MD, MPH
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Dr. Longstreth is a co-investigator on several NIH-fundedstudies.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Myriam Fornage, PhD
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NINDS
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Russell P. Tracy, PhD
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
(1) Kidney Research Institute, University of Washington
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) NIH, travel
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Funding sourceGrant numberRoleyears1)NHLBIHHSN2682015000031Site PI8/15-8/192)NHLBIHHSN2682015000031Site PI1/16-4/183)NHLBIU01 HL084904Central lab director7/09-10/194)NIHUM1 HL120877Central lab director3/16-5/185)NHLBIR01 HL120854Co-PI7/14-4/206)NHLBIR01 HL125032Co-PI8/14-6/187)NIHR01 HL126542Co-PI9/14-5/208)NIHR01 HL126543Co-I6/15-5/189)NIA U01 AG50499Co-I9/15-5/1810)NIAR01 AG052964Co-PI5/16-5/2111)NHLBIHHSN268201800001CPI1/16-6/2012)NIHU01 HL130114Central Lab director5/16-4/2013)NIHR01 AG053325Co-I7/16-4/2014)NINDSUH2 NS100605Co-PI9/16-7/2115)NIHU24 AR071113Co-I12/16-11/2216)NIHR01 HL132947Co-I4/17-3/2117)NIDDKR01 DK112258Co-I9/17-6/2218)NIHR01 HL135625Co-I7/18-5/2219)NIHU01 AG060907Co-I9/18-8/2020)NHLBIHHSN268201800010Central lab director8/18-8/2321)NHBLIHHSN268201800010Central lab director2/19 ? 2/2022)NIHU01 HL146382Central lab director5/19-4/2523)NIGMSP20 GM125498Co-I9/18-7/23
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
(1) Haematologic Technologies, Inc.
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Oscar Lopez, MD
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Grifols,Inc.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIA: P50 AG005133-34; 1P01-AG025204-04; 1RF1 AG052525-01
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Bruce M. Psaty, MD, PhD
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
Psaty serves on the Steering Committee of the Yale Open Data Access project funded by Johnson & Johnson.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
American Journal of Hypertension, editorial board, 2016-
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
Zoll LifeCor, service on DSMB of a clinical trial Johnson & Johnson, service on the steering committee of the Yale Open Data Access Project
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH grants acknowledged in the paper
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Daniel Levy, MD
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
I serve as Editor-in-Chief for International Journal of Cardiology Hypertension
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sudha Seshadri, MD
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIA AG033040, AG049505, AG049607, AG054076, AG052409, AG058589 NINDS NS017950, NS100605
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Joshua C. Bis, PhD
From the Harvard T.H. Chan School of Public Health (M.P.P.), Boston; Department of Neurology (J.J.H., A.S.B., C.L.S., H.J.A., S.S.), Boston University School of Medicine; Framingham Heart Study (M.P.P., J.J.H., A.S.B., C.D., E.R.M., C.L.S., H.J.A., D.L., S.S.), MA; Centre for Human Psychopharmacology (M.P.P.), Swinburne University of Technology; Melbourne Dementia Research Centre (M.P.P.), The Florey Institute for Neuroscience and Mental Health & The University of Melbourne, Australia; Department of Biostatistics (J.J.H., A.S.B.), Boston University School of Public Health, MA; Department of Neurology (C.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento; Departments of Epidemiology (H.H.H.A.) and Radiology and Nuclear Medicine (H.H.H.A.), Erasmus MC, Rotterdam, the Netherlands; Department of Epidemiology (A.P.R., W.T.L., B.M.P.), Fred Hutchinson Cancer Research Center (A.P.R.), Department of Neurology (W.T.L.), Cardiovascular Health Research Unit, Department of Medicine (B.M.P., J.C.B.), and Department of Health Services (B.M.P.), University of Washington, Seattle; Human Genetics Center, Department of Epidemiology (M.F.), Human Genetics & Environmental Sciences, School of Public Health (M.F.), and The Brown Foundation Institute of Molecular Medicine, Research Center for Human Genetics (M.F.), University of Texas Health Science Center, Houston; Departments of Pathology and Laboratory Medicine (R.P.T.) and Biochemistry (R.P.T.), Larner College of Medicine, University of Vermont, Burlington; Department of Neurology (O.L.), School of Medicine, University of Pittsburgh, PA; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle; The Population Sciences Branch of the National Heart, Lung and Blood Institute (D.L.), NIH, Bethesda, MD; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S.), University of Texas Health Sciences Center, San Antonio; Department of Neurology (E.R.M.), Brigham & Women's Hospital; and Harvard Medical School (E.R.M.), Boston, MA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Seshadri [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
*
These authors contributed equally as co–first authors.
These authors contributed equally as co–senior authors.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Long-term radiofrequency electromagnetic fields exposure attenuates cognitive dysfunction in 5×FAD mice by regulating microglial function, Neural Regeneration Research, 18, 11, (2497-2503), (2023).https://doi.org/10.4103/1673-5374.371379
    Crossref
  2. Cognitive impairment and biomarkers of gut microbial translocation in testicular germ cell tumor survivors, Frontiers in Oncology, 13, (2023).https://doi.org/10.3389/fonc.2023.1146032
    Crossref
  3. Comparison of Pairwise Venous and Fingertip Plasma Using Quantitative Proteomics Based on Data-Independent Acquisition, Journal of Proteome Research, 22, 4, (1347-1358), (2023).https://doi.org/10.1021/acs.jproteome.3c00081
    Crossref
  4. sCD14, a marker of immune-inflammation can help to distinguish between psychotic disorders with and without disordered social interaction, Medical Hypotheses, 181, (111190), (2023).https://doi.org/10.1016/j.mehy.2023.111190
    Crossref
  5. Soluble TNFR1 has greater reproducibility than IL-6 for the assessment of chronic inflammation in older adults: the case for a new inflammatory marker in aging, GeroScience, (2023).https://doi.org/10.1007/s11357-023-01006-x
    Crossref
  6. Association between gut permeability, brain volume, and cognition in healthy participants and patients with schizophrenia spectrum disorder, Brain and Behavior, 13, 6, (2023).https://doi.org/10.1002/brb3.3011
    Crossref
  7. Experimental and Clinical Biomarkers for Progressive Evaluation of Neuropathology and Therapeutic Interventions for Acute and Chronic Neurological Disorders, International Journal of Molecular Sciences, 23, 19, (11734), (2022).https://doi.org/10.3390/ijms231911734
    Crossref
  8. Microglia and Astrocyte Function and Communication: What Do We Know in Humans?, Frontiers in Neuroscience, 16, (2022).https://doi.org/10.3389/fnins.2022.824888
    Crossref
  9. Identification of Key Biomarkers and Pathways for Maintaining Cognitively Normal Brain Aging Based on Integrated Bioinformatics Analysis, Frontiers in Aging Neuroscience, 14, (2022).https://doi.org/10.3389/fnagi.2022.833402
    Crossref
  10. Neuroinflammatory Signaling in the Pathogenesis of Alzheimer’s Disease, Current Neuropharmacology, 20, 1, (126-146), (2022).https://doi.org/10.2174/1570159X19666210826130210
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share